HighTower Advisors’s IGC Pharma IGC Stock Holding History

HighTower Advisors’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$2.63K	–	3914
2026 Q1	$2.63K	Buy	+10,000	New	+$2.77K	﹤0.01%	3796

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

HighTower Advisors's IGC Position: Q2 2026 in Review

HighTower Advisors sold out of IGC Pharma (IGC) in Q2 2026, closing a stake of 10,000 shares — an estimated $2.63K sold.

HighTower Advisors first reported a position in IGC in Q1 2026 and held it in 1 quarter. The position peaked at $2.63K in Q1 2026. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

HighTower Advisors reported no remaining IGC Pharma position as of Q2 2026 after selling out during the quarter.
HighTower Advisors sold 10,000 IGC Pharma shares in Q2 2026, an estimated $2.63K.
HighTower Advisors first reported a position in IGC Pharma in Q1 2026 and held it in 1 quarter.
HighTower Advisors's IGC Pharma position peaked at $2.63K in Q1 2026.
36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.